Physician profile
Benjamin Smith
NPI 1326665944
$4,869.53
in general payments reported to CMS, 2019-2025
21 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.81 · 2021: $540 · 2022: $815 · 2023: $1,013 · 2024: $1,073 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,303.88 | 2021-2025 | Precision 1, Precision7, Rocklatan |
| Bausch & Lomb Americas INC. | $424.03 | 2023-2025 | Xiidra, Infuse, Miebo |
| Biotissue Holdings INC. | $352.34 | 2022-2025 | |
| Coopervision INC. | $247.16 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $224.81 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $197.32 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $186.26 | 2021-2025 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $113.03 | 2023 | Tepezza |
| Harrow Eye, LLC | $111.42 | 2025 | Vevye |
| Lkc Technologies, INC. | $110.90 | 2024 | |
| Astellas Pharma US INC | $99.68 | 2023 | |
| Optos, INC. | $94.81 | 2020 | |
| Tearlab Corp | $77.22 | 2022 | |
| Abbvie INC. | $47.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.08 | 2021-2023 | |
| Oyster Point Pharma, INC. | $27.47 | 2025 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $25.33 | 2025 | Xdemvy |
| Amgen INC. | $24.67 | 2024 | Tepezza |
| Thea Pharma INC. | $19.49 | 2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.